Heron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Heron Therapeutics

09/08/2022 14:32

* Heron Therapeutics Inc  HRTX.OQ  reported a quarterly
adjusted
loss of 55 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 50 cents per share.
    * Revenue rose 23.1% to $27.63 million from a year ago;
analysts
expected $24.32 million. 
    * Heron Therapeutics Inc's reported EPS for the quarter was
a loss
of 55 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Heron Therapeutics Inc shares had risen by 28.0% this
quarter and lost 60.9% so far this year.
    * The company reported a quarterly loss of $56.36 million.
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.50          -0.55          Missed
 Mar. 31 2022      -0.48          -0.63          Missed
 Dec. 31 2021      -0.58          -0.54          Beat
 Sep. 30 2021      -0.61          -0.51          Beat